<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Accelerate Your AML Drug Development with Predictive Preclinical Models

Acute Myeloid Leukemia (AML) remains one of the most aggressive blood cancers, requiring innovative approaches to drive therapeutic breakthroughs. This cancer type is difficult due to its complexity and rapid disease progression among other factors.

Finding a single target for all AML patients is extremely difficult because different patients will have different cancer mutations. Genetic heterogeneity complicates treatment therapies and can lead to resistance to therapies. However, there have been recent advancements in AML treatments that include targeted therapies, combination therapies, and immunotherapy.

At Crown Bioscience, we provide predictive in vivo and in vitro preclinical models, and biomarker discovery solutions, to support your AML drug development pipeline.

WHITE PAPER

PDX Dispatch: Acute Myeloid Leukemia PDX Models

Unlock the power of clinically predictive AML PDX models—download the white paper now.

Download Now
cover-aml-pdx-wp

 

Why Choose us for AML
Drug Discovery Research?

icon1-1

Extensive AML patient-derived xenograft (PDX) models to preserve patient tumor heterogeneity for clinically relevant studies

icon2-1

Comprehensive AML cell line-derived xenograft (CDX) models to test therapeutic efficacy using standardized, fully characterized and reproducible cancer cell lines in vivo

icon3-1

Flow cytometry and multi-omics analysis that allow deeper insights into AML pathogenesis and response to therapy

icon4-1

Custom study design and biomarker discovery for tailored solutions to accelerate drug efficacy and resistance profiling

Preclinical AML Models for Translational Success

PDX Models

  • Diverse AML subtypes that retain the genetic and phenotypic characteristics of primary AML tumors
  • Genomic and transcriptomic characterization for targeted therapy insights
  • Drug response tracking for precision medicine applications
pdx-models

CDX Models

  • Standardized and reproducible drug testing for consistent robust results across your studies
  • Well-established and characterized cell lines for evaluating tumor biology, drug efficacy and drug response
  • Rapid model development resulting in quick turnaround times for efficient preclinical research
cdx-models

AML and the Bone Marrow Niche

  • Therapeutic response evaluation against AML samples in a biologically relevant 3D setup, which can modulate therapeutic resistance
  • Tumor killing and immune cell proliferation insights with phenotypic high content imaging analysis, as well as potential off-target effects to the niche components
  • Transition from in vitro to in vivo with our clinically relevant haematological cancer PDX collection
bone-marrow

Advanced Multi-Omics to Enhance AML Drug Discovery

  • Single-cell RNA sequencing and genomics to identify novel AML biomarkers and resistance mechanisms
  • Proteomics and epigenetics to gain insights into disease progression and drug responses
  • AI-powered data analytics to enhance predictive modeling for AML treatment strategies
aml-drug-discovery

AML PDX Study Design

Preclinical models for evaluating AML using patient-derived mononuclear cells (MNCs) in leukemic mice and the subsequent study is designed in the following manner:

full-image(1)
  1. Patient Information MNC Collection
    Mononuclear cells (MNCs) are collected from leukemia patients.
  2. Engraftment into Leukemic Mice
    The patient-derived MNCs are engrafted into immunodeficient (NOD/SCID) mice, to study leukemia progression.
  3. Validation Characterization
    Assessed for leukemia indicators:
    • Cellular phenotypes
    • Histopathological changes
    • Unique biomarkers
  1. Treatment Phase
    Experimental treatments are administered
  2. Endpoints Evaluation
    The study assesses several key outcomes:
    • Survival rates
    • Clinical symptoms
    • Peripheral leukemic burden (measured in blood, lymphoid organs, and other tissues)

Our Complimentary Cancer Model Databases

img-box-1

PDX Model Database

Access 2,500+ global PDX models. Tailor your selections based on indication, drug responses, patient histories, and multiomics data for precision in your studies.

Enter

img-box-2

Organoid Models Database

Utilize 1,000 specialized in vitro models using HUB protocols. Easily access vital PDXO data including histopathology, IC50, and genomics to ensure research accuracy.


Enter

img-box-3

IO Murine Models
Database

Broaden possibilities with 100+ syngeneic, GEMM, tumor homograft models, humanized genetically modified mouse models, and more to enhance immunology outcomes.


Enter

img-box-4

Cell Line and CDX Database

Search from 1000+ cancer cell lines and 200+ CDX models. View and select models available for screening and faster in vitro to in vivo study translation.


Enter

The Bone Marrow Niche in AML: Shielding Leukemia, Hindering Treatment

The bone marrow niche plays a critical role in AML by providing a supportive microenvironment that influences leukemia progression, therapy resistance, and relapse. The bone marrow niche, normally responsible for maintaining healthy hematopoietic stem cells (HSCs), is hijacked by leukemic stem cells (LSCs) in AML. AML cells alter the niche to create a favorable environment for their own survival and proliferation while impairing normal blood cell production.

con-image-v2

LSC Protection and Chemoresistance

  • The bone marrow niche provides a protective shield for AML cells, reducing their sensitivity to chemotherapy, in addition to a hypoxic environment enhancing drug resistance and AML cell survival
  • Cellular interactions, for example, AML cells binding to stromal cells via integrins like VLA-4, help AML cells resist apoptosis and evade immune detection

Immune Evasion

  • AML cells remodel the niche by suppressing immune surveillance mechanisms, allowing leukemia to persist and relapse
  • They recruit regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) to dampen the immune response

Disrupting the Normal Hematopoietic Niche

  • AML cells outcompete healthy HSCs, leading to low blood cell counts seen in AML patients
  • They secrete inflammatory cytokines (IL-6, TGF-β, TNF-α) that promote leukemia growth while impairing normal blood cell production

Therapeutic Targeting of the Bone Marrow Niche

Given its role in drug resistance and disease relapse, targeting the bone marrow niche is an emerging strategy in AML therapy. The bone marrow niche is a key player in AML pathogenesis, promoting leukemic survival, drug resistance, and immune evasion. Therapeutic strategies targeting the niche could improve treatment outcomes and reduce relapse rates in AML patients.

Partner with Us to Drive Your AML Research Forward

From preclinical AML models to multi-omics biomarker discovery, Crown Bioscience delivers cutting-edge solutions for accelerating AML drug development. Accelerate the next generation of AML therapies with comprehensive, end-to-end support. Connect with our seasoned experts today—use the Request Form to discuss your AML research needs!

Contact Us

FAQ About AML Drug Development with
Predictive Preclinical Models

What is Acute Myeloid Leukemia (AML)?

 

Acute Myeloid Leukemia (AML) is an aggressive blood cancer that originates in the bone marrow, causing rapid proliferation of abnormal white blood cells. AML is a highly heterogeneous disease, making preclinical and clinical research essential for discovering effective treatments.

Why is AML research critical for drug development?

 

AML has a high relapse rate and limited treatment options. Developing novel AML therapies, including targeted therapies, immunotherapies, and combination treatments, requires robust preclinical AML models and biomarker-driven research to improve patient outcomes.

How does Crown Bioscience support AML drug discovery and development?

 

Crown Bioscience provides comprehensive preclinical AML research services, including in vitro AML assays, in vivo AML models, AML patient-derived xenografts (PDX), and AML biomarker analysis to accelerate oncology drug development.

What types of preclinical AML models are available?

 

We offer a diverse range of clinically relevant AML models, including:

  • Primary patient samples
  • Patient-derived xenografts (PDX models)
  • Cell line-derived xenografts (CDX models)
  • Syngeneic AML models
  • These models enable predictive AML drug testing, supporting the evaluation of targeted therapies, small molecules, and immunotherapies.

Why are AML patient-derived xenograft (PDX) models important for drug testing?

 

AML PDX models closely replicate patient tumor heterogeneity and disease progression, making them highly predictive for preclinical AML drug screening and precision medicine research.

What functional assays do you offer for AML drug screening?

 

We provide a range of high-throughput AML assays to evaluate drug efficacy, including:

  • AML cell proliferation assays
  • Cytokine profiling for AML immunotherapies
  • AML drug resistance studies

How does Crown Bioscience support biomarker discovery in AML?

 

Our advanced multi-omics capabilities, including genomics, transcriptomics, and proteomics, help identify and validate AML biomarkers, supporting companion diagnostic development and patient stratification.

Can you design a custom AML preclinical study?

 

Yes! We provide fully customizable AML study designs to support your specific research objectives, including target validation, efficacy testing, and combination therapy evaluations.

What types of AML therapies can be tested using your models?

 

Our models support AML drug development across multiple therapeutic modalities, including:

  • Small molecule inhibitors
  • Monoclonal antibodies (mAbs)
  • Bispecific antibodies
  • CAR-T and other cell therapies
  • Epigenetic and immune checkpoint inhibitors

How translational are Crown Bioscience’s AML preclinical models?

 

Our AML models are designed for high clinical translatability, with patient-derived and humanized systems that enhance predictive AML drug research and facilitate successful IND submissions.

How does Crown Bioscience ensure high-quality, reproducible AML study results?

 

We adhere to strict quality control measures, including:

  • Standardized AML study protocols
  • Experienced scientific oversight
  • State-of-the-art imaging and analytics

How can I get started with an AML research study at Crown Bioscience?

 

Contact us today to discuss your AML drug development needs! Our expert team will help design a study tailored to your research goals.

Related Resources

preclinical-solutions

White Paper

Harnessing Integrated Preclinical Solutions to Accelerate Bispecific Antibody Development

download now

HuKemia®-TN-1

Factsheet

HuKemia®



Download Now

pdx-mct

Poster

Characterization of Acute Myeloid Leukemia PDX Models with Hotspot Gene Mutations for Therapeutic Evaluation

download now

preclinical-solutions

White Paper

Harnessing Integrated Preclinical Solutions to Accelerate Bispecific Antibody Development

download now

HuKemia®-TN-1

Factsheet

HuKemia®



Download Now